company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2480834.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2480834.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1313135.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1313135.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1167699.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2948813.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2525001.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5473814.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4306115.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,472205.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,482.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-26055.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-497778.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4803893.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4803893.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4803893.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,810796.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5614689.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,3100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.84
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,3100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.84
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,3048131.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q2,2013-01-01,2013-03-31,2014-05-15 11:24:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.84
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5075029.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5075029.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2925046.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2925046.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2149983.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,-742048.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1632280.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,890232.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1259751.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,452368.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1036.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-53843.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-505175.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,754576.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,754576.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,754576.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,1074637.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-320061.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,2900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,2900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,3048131.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q3,2013-04-01,2013-06-30,2014-08-11 15:22:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5492000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5492000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4624000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4624000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,868000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1344000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2589000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3933000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3065000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-191000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-190000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3255000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3255000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3255000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,1132000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4387000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,3000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.44
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,3000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.44
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,3048131.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.44
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4740000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,265000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5005000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3360000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3360000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1645000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1454000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3794000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5248000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3603000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-383000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-376000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3979000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1295000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2684000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2684000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,534000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3218000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,8862212.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.36
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,8900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.36
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,8900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,2014-01-01,2014-03-31,2015-05-15 16:25:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.36
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2292000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,3500000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5792000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1556000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1556000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4236000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2673000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4545000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7218000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2982000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,18000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,35000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,48000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2934000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2934000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2934000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2934000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14020133.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,2014-04-01,2014-06-30,2015-08-11 16:21:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2810000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2810000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-4498000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-4498000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7308000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3855000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5888000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,6672000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16415000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9107000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,9955937.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.04
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,9955937.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.04
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,10000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.04
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6309000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,30000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,36309000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5948000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5948000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,30361000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3986000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6285000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10271000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,20090000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,6000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,20096000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,399000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,19697000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,19697000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,19697000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14247019.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.38
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.31
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14300000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.38
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6002000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6002000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3348000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3348000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2654000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5111000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5878000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10989000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8335000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8330000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-153000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15546796.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.53
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.53
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15400000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:51:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.53
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5736000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5736000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3753000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3753000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1983000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5460000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6911000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12371000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10388000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10385000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-218000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10167000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10167000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10167000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15589818.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.65
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15600000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.65
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15600000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 16:42:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.65
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3180000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,15000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18180000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-5287000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-5287000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23467000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5608000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8781000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,7885000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22274000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1193000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1193000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-25000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1218000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1218000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1218000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15250154.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16253781.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.03
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23591000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,6000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,29591000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12767000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12767000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16824000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12128000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5521000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,1822000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-1750000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17721000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-897000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,21000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,20000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-877000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,19000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-896000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-896000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-896000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15636387.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.06
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.06
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.06
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,40918000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,40918000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7181000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7181000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,33737000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11990000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3799000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,4292000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20081000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,13656000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,30000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,27000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,13683000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,584000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,13099000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,13099000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,13099000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15636387.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.84
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16400000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.8
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15600000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:42:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.84
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,34083000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,3750000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,37833000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,31833000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11661000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3207000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,4425000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,232000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19525000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,12308000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,26000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,23000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,12331000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,379000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,11952000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,11952000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,11952000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15570740.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.77
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16400000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.73
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15500000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:05:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.77
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,90890000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,-9750000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,81140000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,9837000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,9837000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,71303000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17550000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15762000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,8982000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,725000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,43019000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,28284000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,6000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,28290000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-29008000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,57298000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,57298000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,57298000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15533681.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.69
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16434104.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.49
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15500000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.69
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,51793000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,25000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,76793000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,10765000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,10765000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,66028000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18578000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7525000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,7229000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33332000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,32696000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,27000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-24000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,32672000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,9748000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,22924000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,22924000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,22924000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15257892.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.5
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16165361.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.42
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15300000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.5
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,50108000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,50108000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8910000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8910000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,41198000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,23280000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6684000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,4910000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,422000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35296000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5902000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,40000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,14000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5876000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1373000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4503000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4503000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4503000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15219777.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.3
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16100615.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.28
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:28:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.3
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,63021000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,63021000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4815000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4815000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,58206000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,16669000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8954000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,6850000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7235000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-6452000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33256000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,24950000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,527000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,35000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-492000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,24458000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,9027000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,15431000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,15431000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,15431000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15047917.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.03
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15764360.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.98
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:48:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.03
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,71785000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,-25000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,46785000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,9224000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,9224000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,37561000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12889000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9444000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,4483000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,303000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27119000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10442000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,542000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,39000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-503000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9939000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,854000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9085000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,9085000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,9085000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15102890.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.61
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15908211.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.59
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.61
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,46626000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,46626000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7223000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7223000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,39403000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,15193000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17320000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,4585000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37098000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2305000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,675000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,27000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-648000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1657000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-959000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2616000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2616000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2616000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14819530.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.18
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15478335.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.17
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14500000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.18
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,59296000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,59296000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14074000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14074000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,45222000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,15987000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15265000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,4485000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,2704000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,7388000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-790000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45039000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,183000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,701000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-700000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-517000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3176000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2659000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2659000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2659000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14879040.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.18
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15446827.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.17
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14800000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:50:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.18
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,51337000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,51337000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8621000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8621000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,42716000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13878000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5975000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,4370000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,91000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24314000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,18402000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,9000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-734000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,17668000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3628000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,14040000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,14040000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,14040000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15011159.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.94
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15483037.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.91
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:30:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.94
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56053000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56053000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12456000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12456000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,43597000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,15451000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5859000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,6102000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,432000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,27000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27871000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,15726000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,617000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,121000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-496000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,15230000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2642000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,12588000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,12588000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,12588000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14768625.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.86
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15278651.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.84
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14800000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.86
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,49785000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,49785000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,9554000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,9554000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,40231000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18141000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6375000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,3546000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28062000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,12169000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,686000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,494000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-192000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,11977000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3004000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,8973000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,8973000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,8973000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13925227.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.64
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14418211.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.62
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.64
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56702000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56702000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,18175000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,18175000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,38527000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17228000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8957000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,3109000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29294000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9233000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,665000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,637000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-28000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9205000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2480000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6725000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6725000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6725000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13782720.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.49
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14156627.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.48
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13700000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:50:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.49
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,41147000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,41147000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12137000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12137000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,29010000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18537000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10172000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,2785000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31494000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2484000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,628000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,570000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-58000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2542000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-152000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2390000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2390000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2390000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13668091.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13668091.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:30:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,48258000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,48258000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8025000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8025000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,40233000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,22464000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11306000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,3566000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37336000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2897000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,707000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,468000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,700000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,461000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3358000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2353000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1005000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1005000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1005000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13754516.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.08
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14138733.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.08
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13800000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.08
